OrSense's NBM 200MP non-invasive Hb measurement system more accurate than invasive POC devices

Oct 18 2010

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, presented in an oral presentation at the American Society of Anesthesiologists (ASA) annual meeting in San Diego, results showing that hemoglobin (Hb) measurements obtained by its NBM 200MP, a non-invasive Hb measurement system, showed accurate performance during hemorrhage conditions compared with invasive point of care (POC) devices.

Monitoring of Hb is essential for the detection of anemia and hemorrhage, and is widely used in the ICU, ER, operating and delivery rooms. The current measurement methods are invasive, painful, time consuming and labor intensive, and are inadequate for continuous Hb monitoring, often necessary during emergency situations. Non-invasive measurement of Hb has many advantages including the prevention of pain and potential transmission of infectious diseases, the reduced need for trained personnel and the freedom to take multiple measurements continuously. NBM 200MP offers a unique, breakthrough, non-invasive solution for accurate and quick Hb measurements.

Another study, presented as a poster in the same ASA conference, validated the performance of the non-invasive NBM 200MP for continual, safe and reliable monitoring of oxygen saturation levels, even in extreme cases of low perfusion and weak pulsation, when standard pulse oximeters fail. Thus, the NBM 200MP occlusion-based oximetry may overcome the limitations of pulse oximetry, and improve the ability to detect hypoxemia and related events in ICU, OR and other hospital units. The NBM 200MP oximetry monitor is FDA cleared.

Lior Maayan, CEO of OrSense, said, "The study presented at the ASA meeting substantiates the potential of the non-invasive NBM 200MP for accurate, continual, safe, and easy-to-use monitoring of Hb, in particular under technological-challenging, potentially life-threatening conditions such as hemorrhage. We anticipate that the NBM 200MP will constitute a significant contribution to a safe and efficient critical care patient treatment."